18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer

Öztürk,Hakan; Karapolat,İnanç

doi:10.3892/ol.2015.3903

18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer

Authors:
- Hakan Öztürk
- İnanç Karapolat
View Affiliations

Affiliations: Department of Urology, School of Medicine, Sifa University, Izmir 35240, Turkey, Department of Nuclear Medicine, School of Medicine, Sifa University, Izmir 35240, Turkey
Published online on: November 10, 2015 https://doi.org/10.3892/ol.2015.3903
Pages: 316-322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to retrospectively review the contribution of 18F-fluorodeoxygluose‑positron emission tomography/computed tomography (18F-FDG PET/CT) in the assessment of biochemical recurrence in patients with a diagnosis of local‑stage prostate cancer (PCa) who underwent radical prostatectomy (RP) or received external beam radiation therapy (EBRT). A total of 28 patients who underwent RP or received EBRT for PCa between July 2007 and April 2013, and who underwent 18F‑FDG PET/CT scanning for re‑staging due to biochemical recurrence were included in the present study. The mean age of the patients was 65.07 years and the standard deviation was 7.51 years (range, 51‑82 years). Of the 28 patients, 23 (82.1%) underwent RP and 5 (17.9%) received definitive EBRT. Prior to scanning, all patients were required to fast for 6 h, and ~1 h after the intravenous injection of 555 MBq 18F‑FDG, whole‑body PET scans were performed from the skull base to the upper thighs. Whole‑body CT scans were performed in the craniocaudal direction. 18F‑FDG PET images were reconstructed using CT data for attenuation correction. Histopathology examination or clinical follow‑up was used to confirm any suspicious recurrent or metastatic lesions. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F‑FDG PET/CT were 61.6, 75.0, 61.6, 75.0 and 71.4%, respectively. 18F‑FDG PET/CT can detect local and distant metastases with a high accuracy in the assessment of biochemical recurrence, thus detecting occult metastases and allowing the re‑staging of PCa in the patients receiving definitive treatment. It is considered that 18F‑FDG PET/CT may be useful in re‑assessing the patients with PCa receiving definitive treatment.

View Figures

View References

1	Boyle P and Ferlay J: Cancer incidence and mortality in Europe 2004. Ann Oncol. 16:481–488. 2005. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
3	Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL: ISUP grading committee. The 2005 International Society of Urologic Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242. 2005. View Article : Google Scholar : PubMed/NCBI
4	Hemminki K: Familial risk and familial survival in prostate cancer. World J Urol. 30:143–148. 2012. View Article : Google Scholar : PubMed/NCBI
5	Leitzmann MF and Rohrmann S: Risk factors for the onset of prostatic cancer: Age, location and behavioral correlates. Clin Epidemiol. 4:1–11. 2012. View Article : Google Scholar : PubMed/NCBI
6	Oliver SE, May MT and Gunnell D: International trends in prostate-cancer mortality in the ‘PSA-ERA’. Int J Cancer. 92:893–898. 2001. View Article : Google Scholar : PubMed/NCBI
7	Ilic D, O'Connor D, Green S and Wilt T: Screening for prostate cancer: A Cochrane systematic review. Cancer Causes Control. 18:279–285. 2007. View Article : Google Scholar : PubMed/NCBI
8	Roobol MJ, Roobol DW and Schröder FH: Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/ml or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology. 65:343–346. 2005. View Article : Google Scholar : PubMed/NCBI
9	Heenan SD: Magnetic resonance imaging in prostate cancer. Prostate Cancer Prostatic Dis. 7:282–288. 2004. View Article : Google Scholar : PubMed/NCBI
10	Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 26:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
11	Sharma P, Karunanithi S, Singh Dhull V, et al: Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy. Indian J Nucl Med. 28:178–179. 2013. View Article : Google Scholar : PubMed/NCBI
12	Apolo AB, Pandit-Taskar N and Morris MJ: Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 49:2031–2041. 2008. View Article : Google Scholar : PubMed/NCBI
13	Jadvar H: Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol. 199:278–291. 2012. View Article : Google Scholar : PubMed/NCBI
14	Jadvar H: Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol. 6:317–323. 2009. View Article : Google Scholar : PubMed/NCBI
15	European Association of Urology. Guidelines on Prostate Cancer. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdfAccessed. June 15–2015
16	Cookson MS, Aus G, Burnett AL, et al: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 177:540–545. 2007. View Article : Google Scholar : PubMed/NCBI
17	Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al: SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2012/Accessed. December 02–2013
18	Jadvar H, Desai B, Ji L, et al: Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 37:637–643. 2012. View Article : Google Scholar : PubMed/NCBI
19	Gillies RJ, Robey I and Gatenby RA: Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 49(Suppl 2): 24S–42S. 2008. View Article : Google Scholar : PubMed/NCBI
20	Smith TA: Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 57:170–178. 2000.PubMed/NCBI
21	Effert P, Beniers AJ, Tamimi Y, Handt S and Jakse G: Expression of glucose transporter 1 (GLUT-1) in cell lines and clinical specimen from human prostate adenocarcinoma. Anticancer Res. 24:3057–3063. 2004.PubMed/NCBI
22	Stewart GD, Gray K, Pennington CJ, et al: Analysis of hypoxia-associated gene expression in prostate cancer: Lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol Rep. 20:1561–1567. 2008.PubMed/NCBI
23	Kukuk D, Reischl G, Raguin O, et al: Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models. J Nucl Med. 52:1654–1663. 2011. View Article : Google Scholar : PubMed/NCBI
24	Jadvar H, Ye W, Groshen S and Conti PS: [F-18]-fl [F-18]-Fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med. 22:787–793. 2008. View Article : Google Scholar : PubMed/NCBI
25	Shiiba M, Ishihara K, Kimura G, et al: Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 26:138–145. 2012. View Article : Google Scholar : PubMed/NCBI
26	Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S, Shizukuishi K, Tateishi U, Kubota Y and Inoue T: The potential of FDG PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 25:21–27. 2011. View Article : Google Scholar : PubMed/NCBI
27	Schöder H, Hermann K, Gönen M, Hricak H, Eberhard S, Scardino P, Scher HI and Larson SM: 2-[18F] fluoro-2-deoxyglucose positron emission tomography for detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 11:4761–4769. 2005. View Article : Google Scholar : PubMed/NCBI
28	Chang CH, Wu HC, Tsai JJ, et al: Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate specific antigen relapse after treatment for localized prostate cancer. Urol Int. 70:311–315. 2003. View Article : Google Scholar : PubMed/NCBI
29	Jadvar H, Desai B and Quinn D: Treatment response assessment of metastatic prostate cancer with FDG PET/CT. J Nucl Med. 52(Suppl 1): 431P2011.
30	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
31	Wahl RL, Jacene H, Kasamon Y and Lodge MA: From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 50:122S–150S. 2009. View Article : Google Scholar : PubMed/NCBI
32	Hillner BE, Siegel BA, Shields AF, et al: Relationship between cancer type and impact of PET and PET/CT on intended management: Findings of the national oncologic PET registry. J Nucl Med. 49:1928–1935. 2008. View Article : Google Scholar : PubMed/NCBI
33	Hwang I, Chong A, Jung SI, et al: Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images? Ann Nucl Med. 27:140–145. 2013. View Article : Google Scholar : PubMed/NCBI
34	Minamimoto R, Senda M, Jinnouchi S, et al: The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey. Ann Nucl Med. 27:46–57. 2013. View Article : Google Scholar : PubMed/NCBI
35	Wright JL, Lin DW and Stanford JL: The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate. 71:1631–1637. 2011. View Article : Google Scholar : PubMed/NCBI
36	Koochekpour S, Majumdar S, Azabdaftari G, et al: Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res. 18:5888–5901. 2012. View Article : Google Scholar : PubMed/NCBI
37	Bartoletti R, Meliani E, Bongini A, Magno C and Cai T: Fluorodeoxyglucose positron emission tomography may aid the diagnosis of aggressive primary prostate cancer: A case series study. Oncol Lett. 7:381–386. 2014.PubMed/NCBI
38	Tombal B and Lecouvet F: Modern detection of prostate cancer's bone metastasis: Is the Bone Scan Era Over? Adv Urol. 2012:8931932012. View Article : Google Scholar : PubMed/NCBI
39	Mulders PF and Schalken JA: Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 12:241–246. 2009. View Article : Google Scholar : PubMed/NCBI
40	Ryan CJ, Shah S, Efstathiou E, et al: Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 17:4854–4861. 2011. View Article : Google Scholar : PubMed/NCBI
41	Rabbani SA, Gladu J, Harakidas P, Jamison B and Goltzman D: Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer. 80:257–264. 1999. View Article : Google Scholar : PubMed/NCBI
42	Oyama N, Akino H, Suzuki Y, et al: Prognostic value of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol. 4:99–104. 2002. View Article : Google Scholar : PubMed/NCBI
43	Meirelles GS, Schöder H, Ravizzini GC, et al: Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing prostate cancer. Clin Cancer Res. 16:6093–6099. 2010. View Article : Google Scholar : PubMed/NCBI
44	Jadvar H, Xiankui L, Shahinian A, et al: Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 4:91–97. 2005.PubMed/NCBI
45	Morris MJ, Akhurst T, Osman I, et al: Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 59:913–918. 2002. View Article : Google Scholar : PubMed/NCBI
46	Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK and Quinn DI: Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 54:1195–1201. 2013. View Article : Google Scholar : PubMed/NCBI
47	El Fakhri G, Surti S, Trott CM, Scheuermann J and Karp JS: Improvement in lesion detection with whole-body oncologic time-of-flight PET. J Nucl Med. 52:347–353. 2011. View Article : Google Scholar : PubMed/NCBI